Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug afimkibart tested for Long-Term arthritis control

NCT ID NCT07620392

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 18, 2026 · Updated 4 times

Summary

This study is testing the long-term safety and effectiveness of a drug called afimkibart in people with moderate to severe rheumatoid arthritis. Participants have already taken afimkibart in a previous study and will continue taking it. The goal is to see if the drug remains safe and helps control arthritis symptoms over a longer period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
afimkibart (a drug)
What this could lead to
If successful, this could show that afimkibart is a safe and effective long-term treatment option for people with moderate to severe rheumatoid arthritis who haven't responded well to other therapies.
What could go wrong
This is a Phase 2 extension study with only 120 participants, so results may not apply to everyone. Long-term side effects are still unknown, and the drug may not work as well over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jul 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Completed the treatment period of the parent study * Agreement to adhere to the contraception requirements * Continued to be evaluated at the follow-up visit of the parent study and achieved improvement in the SJC66/TJC68 relative to baseline Exclusion Criteria: * Withdrawal of consent and/or premature discontinuation from parent study * Any permanent discontinuation of study drug in parent study * Use of a prohibited therapy during the parent study * Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude participant participation in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate to severe rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Accurate Clinical Management LLC

    RECRUITING

    Houston, Texas, 77089, United States

  • Accurate Clinical Research Inc.

    RECRUITING

    Lake Charles, Louisiana, 70605, United States

  • Centrum Kliniczno-Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spó?ka Partne

    RECRUITING

    Elblag, 82-300, Poland

  • Centrum Medyczne Reuma Park

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-665, Poland

  • DM Clinical Research

    RECRUITING

    Tomball, Texas, 77375, United States

  • Nzoz Bif-Med

    RECRUITING

    Bytom, 41-902, Poland

  • Reumatop Grzegorz Rozumek Karin Pistorius Spolka Jawna

    RECRUITING

    Wroclaw, 52-210, Poland

  • Twoja Przychodnia NCM

    RECRUITING

    Nowa Sól, 67-100, Poland

  • West Broward Rheumatology Associates, Inc.

    RECRUITING

    Tamarac, Florida, 33321, United States

  • Zespol Poradni Specjalistycznych REUMED filia nr 1 Wallenroda

    RECRUITING

    Lublin, 20-607, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.